Agenda

MASTERCLASSES / WORKSHOPS
Monday, 26 February 2018
CONFERENCE DAY 1
Tuesday, 27 February 2018
CONFERENCE DAY 2
Wednesday, 28 February 2018

Registration & Light Breakfast

Best Practices in Gx and Biosimilar CI

Baljit Singh, Ph.D., Managing Director and Partner, INOVIS (formerly Director Insights, Novartis Pharma AG)
Dr. Satish Kumar, Head, CI Strategies, Generics & Biosimilars, INOVIS

This interactive workshop session will enable you to:

• Set up a best-in-industry Gx/biosimilar RI and CI tracking program
• Understand Gx / Biosimilar product development and entry strategies
• This session would focus on the key issues facing the originators / Gx / Biosimilars and their strategies
• How this translates into intelligence options
• What kind of intelligence can be obtained
• This session will be built around real world examples / case studies

This workshop session, will give participants first-hand insights from combined +25 years of experience helping Big Pharma optimize their late-life cycle strategies – i.e. enabling companies to protect and optimize their assets. This interactive session will cover Gx / biosimilar clinical, regulatory, commercial, IP and data exclusivity strategies, the intelligence options available (what, where, why) and actions.

Lunch

Integrating Competitive Intelligence and Business Strategy to Enhance Valuable Decision Making

Dr. Avner Barnea, Senior Lecturer, MBA Program, Netanya Academic College, Israel

Competitive Intelligence (CI) and Business Strategy (BS) are expected to be managed in close cooperation and in greater integration, but as we can extensively learn from many case studies, this is not the current situation. How can corporations do better?

The first part of this session will focus on a model of integration between CI and BS, to create the best value to the decision-making process in the corporation. The second part will be devoted to a comprehensive analysis of a case study that will be presented and discussed in the class through active involvement of the attendees in order to make CI and BS professionals ambassadors of the desired change.

Masterclasses/Workshops Conclude

Good Morning! Caffeinate, Nosh & Say Hello in Exhibition Hall


Plenary Session: Keynote Presentations & Keynote Live Debate

Chairpersons’ Opening Remarks

Visionary Keynote: What Is Your MVP? Pharma Meets Silicon Valley. Convergence of Technology in the Biopharmaceutical World

Michael Pröschel, Head Northern Europe and General Manager, Vifor Pharma

The combination of data and analytics is being hailed as the missing key to unlock new sources of healthcare value and innovation.

When Pharma and Silicon Valley meet slow and ultra-fast innovation cycles converge. Are our competitive intelligence processes prepared to see “beyond the pill”? This presentation will give you an overview of some of the changes and challenges the pharmaceutical industry will be facing by 2020 and how they may affect how you do your business.

Refresh & Connect in Exhibition Hall

Keynote: Live Debate with Top Influencers on Hot Topics

Dr. Rachid Benhamza, Director Product Management, Helsinn Healthcare
Daniel Cho, Director Marketing, Global Pricing & Competitive Portfolio Analytics, Philips Healthcare
Jennifer Cummins, Director of Market Research & Competitive Insights, Vifor Pharma
Dr. Jacob Falck Hansen, Ph.D., Vice President Competitive Intelligence Diabetes, Novo Nordisk A/S
Dr. Sara Panigone, Head of Global Competitive Intelligence, Chiesi Farmaceutici S.p.A.
Dr. Pablo Prados, Integrated Care, Global Biologics Division, Sanofi
Nicolas Py, Director, Head of Market Intelligence & Group Strategic Committee Facilitator, Debiopharm S.A.
Rafaat Rahmani, President, Lifescience Dynamics
Dr. Alfred Reszka, Executive Director & Head, Global Competitive Intelligence, Merck/MSD
Dr. Heresh Rezavandi, BSc. MSc. Ph.D., Head of Strategic Intelligence, Foresight, UCB Pharma

Does Intelligence Impact Strategy?

When in the Strategy Making Process is Strategic Intelligence Most Needed and Impactful?
Should CI be Outsourced or Kept In-House?
Which Model is Best? Brand-focused vs TA- focused vs Center of Excellence Models
Does your Company have a Counter-Intelligence System?
Does Insights Enhance or Stifle Innovation?
And More!

TABLE TALKS SESSION 1

(MAY CHOOSE 1 OF 4 CONCURRENT NETWORKING TABLE TALKS)
TABLE TALK 1
Social Media CI
Maritta Sauer, Director Global Business Intelligence, Merck
TABLE TALK 2
Increasing FTEs Without Increasing FTEs: How to Expand CI Activities Within the Company
Alice Pietralunga, Junior Competitive Intelligence Advisor, Chiesi Farmaceutici S.p.a.
TABLE TALK 3
What CI Can Learn From MR...’The Best of Enemies’
Jennifer Cummins, Director of Market Research & Competitive Insights, Vifor Pharma
TABLE TALK 4
TBA
Uwe-Peter Weitzel, Head Scientific Intelligence - External Innovation Biopharma, Merck Group (Invited)

Networking Luncheon


Streamed Presentations: Case Studies, Technology, and Trends

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT TRACKS

TRACK A

So What? – How to Turn CI to Strategic Brand Recommendations

Ryan Tohill, EMEA Business Insights Manager, Janssen

Competitive Intelligence has been a key pillar of business insight for many years however have we used it as well as we could?

Having an strong view of competitor activity alone is not enough, it is important to ensure as a BI team we supply not only data but the “so what.”
Using case studies this session will look at how to engage internal customers and ways to successfully add CI to your holistic insights package.

TRACK B

Mobile Solutions for Competitive Intelligence: Should You Care?

Bruno Larvol, President, The Larvol Group

• Mobile apps promise uninterrupted access to data and increased productivity; in the field and at conferences, apps can be an especially powerful tool.

• Most industries have recognized the promise of mobile apps; however some (like pharma) have been slower to adopt, in part due to compliance concerns.
• Relevant apps for the pharma CI community are beginning to gain some ground; we’ll examine the current landscape and discuss the use cases being explored by other vendors.
• Introducing the Larvol App: We’ve worked with our customers to build the first fully integrated pharma mobile app, providing comprehensive coverage that includes clinical and commercial info, disease area pipelines, KOL news, and conference data …and it’s free.

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT TRACKS

TRACK A

Real World Data Wars - The CI Perspective

Helen Smith, Senior Director, Global Market Research, Daiichi Sankyo

TRACK B

“Goldilocks and the Three CI Bears”: A Perspective From Dig Worldwide on “Just–Right” Intelligence

Tony Nagle, Co-Founder, Dig Worldwide Ltd.

• A definition of “just-right” intelligence

• Competitive Intelligence cycle revisited
• Obstacles that get in the way of “just-right” intelligence
• Getting it “just right” (or at least trying) within your organisation

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT TRACKS

TRACK A

Interplay Between Competitive Intelligence and Competition Law

Mukundan Bharathan, Regional General Counsel - Europe, Dr. Reddy’s Laboratories SA

Competitive intelligence (CI) is the action of defining, gathering, analyzing, and distributing intelligence about products, customers, competitors, and any aspect of the environment needed to support executives and managers in strategic decision making for an organization.

Companies need to be mindful of certain information and the Antitrust Guidance notes intends to give guidance on how to comply with antitrust law when collecting Competitive Intelligence.

• How to handle competitively sensitive information
• Prohibition on anti-competitive arrangements applies – Article 101 TFEU
• Inter-relationship cartels/information exchange
• Antitrust Guidance on competitive Intelligence
• Recent case laws under Competition Law

TRACK B

Rare Disease Portfolio Optimisation

Joanne Taylor, Ph.D., VP, Head of Neuroscience & Rare Disease, Prescient Healthcare Group
Elisavet Primpidou, Ph.D., Head of Business Development, Europe, Prescient Healthcare Group

• Rare diseases, defined in the EU as affecting fewer than 1/2,000 individuals, comprise between 500 and 8,000 separate diseases and collectively affect approximately 350 million people globally, half of whom are children. Despite the small number of patients per individual disease, regulatory and pricing incentives to tackle these neglected and usually serious conditions have led to an increasingly crowded landscape

• Companies looking to optimise a rare disease portfolio, commonly through partnering, need to consider many factors in addition to the competition including:

    o Identification of and access to patients
    o Quality of the scientific and clinical data
    o How an asset fits within the existing portfolio
    o Whether the unique needs of patients, caregivers, physicians and payers are likely to be met
    o How developers and manufacturers of other rare disease brands have succeeded or failed and
    o How the future landscape is likely to be affected by scientific and clinical advancement as well as market activity

• The presentation will discuss some of the key considerations and challenges when supporting companies looking to develop an optimal rare disease portfolio strategy

Refuel & Rejuvenate in Exhibition Hall

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT TRACKS

TRACK A

The State of Pharmaceutical R&D: Shifts, Trends and Prospects

Alexander Roland, Portfolio Competitor Insights and Analytics Director, GlaxoSmithKline

TRACK B

Leveraging the Power of CI in MA P&R Assessment

Laetitia Bodivit MSc, MA, Director, Lifescience Dynamics
Pharma Client Co-Presenter TBA

Developing a CI tool kit to better integrate CI into the evaluation and assessment of drug candidates

• Key drivers for integrating CI in MA P&R assessments:

    o Unmet need from customers (Patients, Prescribers, Payers, Regulators & Care Givers)
    o Potential differentiation criteria
    o Commercial viability

• Benefits of integrating CI in MA P&R assessments:

    o Better access to planned label by clinical CI
    o Better planning for generic launches
    o CI with payers and purchases to help product gains access and pricing

• Case study

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT TRACKS

TRACK A

The Value of Stakeholder Engagement – Best Practices

Almudena Berzosa, General Market Intelligence Lead, CM/SM Center of Excellence, Global Enterprise Procurement, Johnson & Johnson Family of Companies (Invited)

TRACK B

Competitive Insights Into the Future of Drug Delivery Devices

Cinda Steele, Senior Vice President, Life Sciences, Fletcher/CSI

1. Learn about new developing medication delivery technologies and how companies are able to develop a competitive differentiation using novel delivery devices

2. Learn how to work with internal organizational device decision processes to embed competitive insight into the decision process
3. Learn how to better predict your competitors initiatives by better understanding egulatory pathways and device developmental timelines
4. Learn to better understand what has worked and hasn’t worked with regards pharma/device partnerships and how to help your company select the right device partner
5. Learn about tools and techniques available to you to help you stay on top of your competitor device development initiatives

PARTICIPANTS MAY CHOOSE 1 OF 2 CONCURRENT TRACKS

TRACK A

Hands-On! LEGO® Serious Play® Methodology Applied in Pharma

Dr. Sara Panigone, Head of Global Competitive Intelligence, Chiesi Farmaceutici S.p.A.

The LEGO® SERIOUS PLAY® methodology is an innovative process designed to enhance innovation and business performance, based on the belief that everyone can contribute to the discussion, the decisions and the outcome.

Research shows that this kind of hands-on, minds-on learning produces a deeper, more meaningful understanding of the world and its possibilities. After a brief overview of the methodology and the rationale behind, examples of how it has been used to facilitate workshops aimed at defining a shared vision and guiding principles, or at identifying project risks and counter-strategies within a Pharma company will be presented.

TRACK B

CI Prediction Tracking and Opportunity Assessment: How to Predict the Short Term and Influence the Long Term Future

Dr. Heresh Rezavandi, BSc. MSc. Ph.D., Head of Strategic Intelligence, Foresight, UCB Pharma

Tracking CI predictions made about the short term future allows your function to understand the accuracy and

quality of your CI program as well as providing a KPI to your stakeholders the confidence you can bring them when pressure testing their strategy and providing early signals of risks and opportunities in your competitive environment.

Speed Business Networking

Cocktail Reception: Drink, Eat & Be Merry!

Good Morning! Caffeinate, Nosh & Say Hello in Exhibition Hall


Formats: Table Talks, Solving a CI Challenge, and Group Discussions

TABLE TALKS SESSION 2

(MAY CHOOSE 1 OF 4 CONCURRENT NETWORKING TABLE TALKS)
TABLE TALK 1
Social Media CI
Maritta Sauer, Director Global Business Intelligence, Merck
TABLE TALK 2
Increasing FTEs Without Increasing FTEs: How to Expand CI Activities Within the Company
Alice Pietralunga, Junior Competitive Intelligence Advisor, Chiesi Farmaceutici S.p.a.
TABLE TALK 3
What CI Can Learn From MR...’The Best of Enemies’
Jennifer Cummins, Director of Market Research & Competitive Insights, Vifor Pharma
TABLE TALK 4
TBA
Uwe-Peter Weitzel, Head Scientific Intelligence - External Innovation Biopharma, Merck Group (Invited)

Refuel & Rejuvenate in Exhibition Hall

Solving a CI Challenge

Invigorate your innovation by solving a simulated CI project in a real-world environment. Participants will work in teams guided by veteran CI leaders. Background, tools, techniques, and strategy will be provided. At the end, each group will deliver a final presentation. This will energize you!
Team 1:
    Marc Limacher, MBA, Founder and CEO, INOVIS
    Dr. Baljit Singh, Managing Director and Partner, Lifesciences, INOVIS (formerly Director Insights, Novartis Pharma AG)
    Pharma Representative TBA

    In an unpredictable and ever-changing industry, our ability to develop and pressure-test assumptions against a known (or sometimes unknown) competitor provides valuable insight that can shape strategy.

    Join us for what will be an exciting, hands-on, innovative workshop “outside of the norm” as we simulate a business-critical scenario to test your creativity, adaptability, and of course, challenge your competitive streak!

    As part of this workshop you will have the opportunity to:

    – Leverage your pharma experience, in a pertinent non-pharma (and entertaining) setting, working in one of many cross-functional teams on a series of time-sensitive business activities

    – Experience first-hand, the live development of brand / lifecycle strategy and the various impact factors that can influence response

    – Facilitated by agency and industry experts, identify learnings and best-practices that you can take back and implement into your daily practice

    The Scenario: You have been summoned into a meeting with your Franchise Team after an intense two weeks compiling a market overview for an area previously unexplored. Interestingly, your Finance & Business Development colleagues are attending today’s meeting and you notice that your General Manager has been copied into the meeting invitation. It appears that something big will be revealed…

Team 2:
    Dave Alderman, President, Molekule Consulting
    Dr. Daniel Pascheles, CEO, Molekule Consulting

    In this workshop we will work on two cases studies and prepare CI plans to support these projects. These are the two cases:

    Case Study 1 – In-licensing Project

    Background: Your company is in the process to in-license a Phase II ready compound in the oncology IO space. The product is an inhibitor and will be second or third to market.

    You have been given 8 weeks to prepare a completive assessment for the space and prepare a “pre-diligence” CI report for your managements.

    Case Study 2 – In-line CI Project

    Background: Your company is a leader in the Diabetes Type II space. Your lead asset is a DPP IV compound and is the key revenue driver for your company. The annual revenue of your compound is $3bn and is planned to grow around 8% Y/Y for the next 3 years.

    DPP IV molecules are currently the standard of care approach but a new MOA (SGLT2) is nibbling on your market share. Additionally, the payers in the US put a lot of pressure on pricing / reimbursements. You are currently preparing the annual CI plan and budget for the Global Brand Leader.

Networking Luncheon

Announcement of Raffle Prize Winners

Presentations by the “Solving a CI Challenge” Groups

TBA

Sheila Campos, Vice President Global Commercial Analytics & Insights, Bayer (Invited)

Sources of CI Information in a Hyper-Connected World to Inform Strategy and Decision Making

Dennis Engelke, Director, Business Analysis & Insight, Jazz Pharmaceuticals
Vivan Ho, Portfolio Strategy Manager, Elanco
Lubos Marek, Head of Global Marketing Operations & Launch Excellence, Alexion Pharma GmbH (Invited)
Massimo Orlando, International Business Support Manager, Alfasigma (Invited)
Peter Elsig Raun, Senior Director, Market Insights & Analytics, GN ReSound A/S (Invited)
Cátia Santos, Head of Marketing & Zurampic Champion, Gruenenthal (Invited)
Andrew White, Associate Director, Competitive Insights, Novartis

Livepolling Power Panel: Review and Discussion of the Most Controversial and Important Topics Over the Two Days

(panelists are Advisory Board Members)
Dr. Rachid Benhamza, Director Product Management, Helsinn Healthcare
Daniel Cho, Director Marketing, Global Pricing & Competitive Portfolio Analytics, Philips Healthcare
Jennifer Cummins, Director of Market Research & Competitive Insights, Vifor Pharma
Dr. Jacob Falck Hansen, Ph.D., Vice President Competitive Intelligence Diabetes, Novo Nordisk A/S
Dr. Sara Panigone, Head of Global Competitive Intelligence, Chiesi Farmaceutici S.p.A.
Dr. Pablo Prados, Integrated Care, Global Biologics Division, Sanofi
Nicolas Py, Director, Head of Market Intelligence & Group Strategic Committee Facilitator, Debiopharm S.A.
Dr. Alfred Reszka, Executive Director & Head, Global Competitive Intelligence, Merck/MSD
Dr. Heresh Rezavandi, BSc. MSc. Ph.D., Head of Strategic Intelligence, Foresight, UCB Pharma

Conference Concludes